<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143751</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0474</org_study_id>
    <nct_id>NCT03143751</nct_id>
  </id_info>
  <brief_title>Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients</brief_title>
  <acronym>COBI</acronym>
  <official_title>Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients Study Protocol for a Multicenter Randomized Open-label Trial With Blinded Adjudication of Primary Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic brain injury (TBI) is a major cause of death and severe prolonged disability.
      Intracranial hypertension (ICH) is a critical risk factor of bad outcomes after TBI.
      Continuous infusion of hyperosmolar therapy has been proposed for the prevention or the
      treatment of ICH. Whether an early administration of continuous hyperosmolar therapy improves
      long term outcomes is uncertain. The aim of the current study is to assess the efficiency and
      the safety of continuous hyperosmolar therapy in TBI patients.

      The COBI trial is the first randomized controlled trial powered to investigate whether
      continuous hyperosmolar therapy in TBI patients improve long term recovery.

      Hypothesis

      Patients treated with early continuous hyperosmolar therapy have reduced morbidity and
      mortality rates compared to those receiving standard care alone after traumatic brain injury.

      Research Questions

        1. Does early continuous hyperosmolar therapy reduce morbidity and mortality rates at 3 and
           6 months after TBI assessed by the GOSE questionnaire?

        2. Does early continuous hyperosmolar therapy prevent intracranial hypertension?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Traumatic brain injury (TBI) is a major cause of death and severe prolonged
      disability. Intracranial hypertension (ICH) is a critical risk factor of bad outcomes after
      TBI.

      Continuous infusion of hyperosmolar therapy has been proposed for the prevention or the
      treatment of ICH. Whether an early administration of continuous hyperosmolar therapy improves
      long term outcomes is uncertain. The aim of the current study is to assess the efficiency and
      the safety of continuous hyperosmolar therapy in TBI patients.

      Methods The COBI (Continuous hyperosmolar therapy in traumatic brain-injured patients) trial
      is a multicenter, randomized, controlled, open-label, two-arms study with blinded
      adjudication of primary outcome. Three hundred and seventy patients hospitalized in Intensive
      Care Unit with a traumatic brain injury (Glasgow Coma Scale ≤ 12 and abnormal brain CT-scan)
      are randomized in the first 24 hours following trauma to standard care or continuous
      hyperosmolar therapy (NaCl 20%) plus standard care. Continuous hyperosmolar therapy is
      maintained for at least 48 hours in the treatment group and continued for as long as is
      necessary to prevent intracranial hypertension. The primary outcome is the score on the
      Extended Glasgow Outcome Scale (GOS-E) at 6 months. The treatment effect is estimated with
      ordinal logistic regression adjusted for pre-specified prognostic factors and expressed as a
      common odds ratio.

      Discussion The COBI trial is the first randomized controlled trial powered to investigate
      whether continuous hyperosmolar therapy in TBI patients improve long term recovery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Masking: Open label , Masked Roles: Subject and Outcomes assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Score on the Extended Glasgow Outcome Scale (GOS-E) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>The GOS-E is a scale measuring the neurological recovery after traumatic brain injuries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate in ICU</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate in ICU</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GOS-E</measure>
    <time_frame>3 months</time_frame>
    <description>The GOS-E is a scale measuring the neurological recovery after traumatic brain injuries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional independence measure</measure>
    <time_frame>3 months</time_frame>
    <description>Scale measuring the autonomy of patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional independence measure</measure>
    <time_frame>6 months</time_frame>
    <description>Scale measuring the autonomy of patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36</measure>
    <time_frame>28 days</time_frame>
    <description>Scale measuring the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36</measure>
    <time_frame>3 months</time_frame>
    <description>Scale measuring the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36</measure>
    <time_frame>6 months</time_frame>
    <description>Scale measuring the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with anterograde amnesia</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with anterograde amnesia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial pressure control</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood level of sodium</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood osmolality</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of thrombo-embolic events</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute kidney injury</measure>
    <time_frame>28 days</time_frame>
    <description>KDIGO 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of centropontine myelinolysis</measure>
    <time_frame>28 days</time_frame>
    <description>Diagnosis on MRI realized in case of clinical suspicion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Moderate to Severe Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Continuous hyperosmolar therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard cares plus continuous hyperosmolar therapy (NaCl20%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard cares alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl20% (Continuous hyperosmolar therapy)</intervention_name>
    <description>Early intravenous administration (&lt;24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)
1-hour bolus (15 g if Na+ &lt; 145 mmol/L; 7.5 g if 145 &lt; Na+ &lt; 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+&lt; 150 mmol/L, reduced to 0.5 g/L if 150 &lt; Na+ &lt; 155 mmol/L, Discontinuation when 155 mmol/L&lt;Na+</description>
    <arm_group_label>Continuous hyperosmolar therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old

          -  Moderate to severe traumatic brain injury defined as the association of a Coma Glasgow
             Scale ≤ 12 together with a traumatic abnormal brain CT-scan

          -  Time to inclusion inferior to 24 hours

          -  Informed consent (or emergency procedure)

        Exclusion Criteria:

          -  dependence for daily activity

          -  Coma Glasgow Scale of 3 and fixed dilated pupils

          -  associated cervical spine injury

          -  imminent death and do-not-resuscitate orders

          -  pregnancy.

          -  Major not legally responsible

          -  Oedemato-ascitic decompensation of hepatic cirrhosis

          -  State of hydro-sodium retention secondary to heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Huet, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lasocki Sigismond, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Geerraerts, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Laffon, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Seguin, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Dahyot, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Poitiers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre François Perrigault, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Denis Moyer, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Beaujon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tarek SHARSHAR, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Saint-Anne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Roquilly, PU-PH</last_name>
    <phone>02.53.48.22.30</phone>
    <email>antoine.roquilly@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karim Asehnoune, PU-PH</last_name>
    <phone>02.44.76.68.90</phone>
    <email>karim.asehnoune@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigismond lasocki, MD.PhD</last_name>
      <email>sigismond@lasocki.com</email>
    </contact>
    <investigator>
      <last_name>Sigismond Lasocki, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brest Hopital La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Huet, MD.PhD</last_name>
      <email>olivier.huet@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Huet, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Denis Moyer, MD</last_name>
      <email>moyer.jeandenis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jean-Denis Moyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Francois Perrigault, MD</last_name>
      <email>pf-perrigault@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Francois Perrigault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Roquilly, MD</last_name>
      <phone>02 40 08 22 30</phone>
      <email>antoine.roquilly@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Karim Asehnoune, MD.PhD</last_name>
      <phone>02 44 76 68 90</phone>
      <email>karim.asehnoune@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Antoine Roquilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tarek SHARSHAR, MD.Ph</last_name>
      <email>tsharshar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tarek SHARSHAR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire Dahyot-Fizelier, MD.PhD</last_name>
      <email>claire.dahyot-fizelier@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Claire Dahyot-Fizelier, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes-Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Seguin, MD.PhD</last_name>
      <phone>02 99 28 42 46</phone>
      <email>philippe.seguin@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Seguin, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Hôpital Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GEERRAERTS, MD.PhD</last_name>
      <email>geeraerts.t@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas GEERRAERTS, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Laffon, MD.PhD</last_name>
      <email>laffon@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Laffon, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

